Does Your Insurance Cover Zepbound?
HOW TO FIND OUT
Does Your Insurance Cover Zepbound?
HOW TO FIND OUTCall Your Insurance Provider 📞
Call the number on your insurance card and ask:
- "Is tirzepatide (Zepbound) on my plan's formulary?"
- "Do you cover it for weight management, or only for diabetes?"
- "What tier is it on?" (lower tier = lower copay)
- "Is prior authorization required?"
Pro tip: Write down the representative's name and any reference number. Verbal confirmations aren't binding, but documentation helps if there's a dispute later.
What Is a Formulary?
A formulary is your insurance plan's list of approved medications. If Zepbound isn't on your formulary, your plan won't cover it—even with a prescription.
The reality: Among large employers, coverage of GLP-1 medications like Zepbound for weight loss is limited: 43% of firms with 5,000+ workers, and 16% of firms with 200–999 workers (2025) cover them.4 Many plans explicitly exclude weight-loss drugs entirely.
Common requirements: BMI ≥30 or ≥27 + comorbidity, plus documented lifestyle changes (the required length varies by plan)
⚠️ 2026 Open Enrollment Alert
Some employers and insurers (for example, Blue Cross Blue Shield of Massachusetts, Health New England and Fallon Health) dropped or restricted GLP-1 weight loss coverage for 2026. If you're choosing a plan now, verify Zepbound coverage BEFORE enrolling.
Ask your HR or insurer: "Does this plan cover tirzepatide (Zepbound) for weight management in 2026?"
Which Insurers Cover Zepbound?
Coverage varies significantly by insurer and plan type. In 2025, 43% of firms with 5,000+ workers, and 16% of firms with 200–999 workers (2025) covered GLP-1s for weight loss. For a complete breakdown of which insurers cover Zepbound and their requirements, see our insurance directory.
Medicaid Coverage Guide
State-by-State Coverage
Only 13 states (as of January 2026) cover GLP-1s for weight loss through Medicaid,8 and the landscape is shifting—some states are adding coverage while others are cutting it due to costs.9
BALANCE Model: Voluntary for states, which can join between May 2026 and January 1, 2027; no participating state has been confirmed. Check with your state Medicaid office.12
Medicaid criteria vary by state and can be stricter than commercial plans, and coverage can change mid-year. Always verify current coverage with your state.
Medicare Coverage Guide
Medicare Coverage Is Changing
Medicare and weight-loss GLP-1s: the Medicare GLP-1 Bridge
Through the Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027), a temporary CMS demonstration that runs outside the Part D benefit, people with eligible Part D coverage can get Wegovy, Foundayo or the Zepbound KwikPen for weight loss for $50 a month, if they meet CMS’s eligibility criteria and their prescriber gets prior authorization.
- Zepbound: Zepbound KwikPen only (not vials or single-dose pens).
- Who qualifies: Age 18+ and BMI ≥35; or BMI ≥30 with HFpEF, uncontrolled high blood pressure or CKD stage 3a+; or BMI ≥27 with prediabetes, a prior heart attack or stroke, or symptomatic PAD.
- Who doesn’t: Not eligible if you have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH with moderate-to-advanced liver fibrosis (F2–F3), or if your Part D plan paid for a GLP-1 for you at any time in 2026.
- Cost: $50 per monthly fill. Does not count toward the Part D deductible or out-of-pocket cap. Extra Help (LIS) does not lower it. Not eligible for the Medicare Prescription Payment Plan. Coupons and discount programs can’t be applied.
- No opt-in needed: Part D plans and pharmacies don’t opt in, and you don’t enroll separately; your prescriber must get prior authorization.
- If it’s denied: No appeals process for a Bridge prior-authorization denial: your prescriber can resubmit with more information (Part D appeal rights for Part D coverage decisions still apply).
Source: CMS, Medicare GLP-1 Bridge · Facts in this box verified October 5, 2026
Sleep apnea: Your Part D plan may cover Zepbound for moderate-to-severe sleep apnea, usually with prior authorization. If you have OSA with BMI ≥30 and AHI ≥15, you may qualify through your Part D plan. Learn more about the OSA pathway →
Does your employer plan exclude all weight loss meds?
If your employer-sponsored plan excludes all weight loss medications, you can advocate for policy change. Request that your HR department add GLP-1 coverage for the next enrollment period—and encourage coworkers to do the same.
Download HR Request Letter (PDF) →Download Coworker Sample Letter (PDF) →Learn more about fighting weight loss exclusions →
Filing for Prior Authorization
HOW TO GET PREPARED
Filing for Prior Authorization
HOW TO GET PREPAREDWhat Is Prior Authorization?
Prior authorization (PA) is your insurer's way of pre-approving expensive medications before they'll cover them. For Zepbound, this means your doctor submits documentation proving you meet the medical criteria—and the insurer decides whether to pay.
Why it matters: A well-prepared PA submission is the difference between approval and denial. Missing documentation, incorrect codes, or incomplete medical history are common reasons Zepbound PAs get rejected. Get the PA checklist →
What Your Doctor Needs
- Current, dated BMI (plus your baseline BMI before any GLP-1)
- Comorbidity diagnoses (hypertension, diabetes, sleep apnea, high cholesterol)
- Lifestyle modification documentation (the required length varies by plan)
- Prior weight-loss medications tried (if any)
- Letter of medical necessity
Timeline: Most employer and ACA plans must decide within 15 days (72 hours if urgent). Follow up by day 5.
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get starteddenied approved
Honest Care helps patients fight back:
Evidence-backed appeal letters — plus personalized guidance to appeal with confidence.
Once You're Approved
SAVINGS & MAINTENANCE
Once You're Approved
SAVINGS & MAINTENANCEYou're Approved — Now Maximize Your Savings
With commercial insurance and the Lilly savings card, you can pay as little as $25/fill for Zepbound. Here's how to activate it and avoid pharmacy surprises.
How to activate your Zepbound savings card
With insurance coverage: As low as $25/month
- Max savings: $100 per 1-month fill; $1,300/year (2026 terms)
- Up to 13 fills per calendar year
Eligibility requirements:
- Commercial insurance that covers Zepbound
- Not for Medicare, Medicaid, TRICARE, VA or other government insurance
- Other program terms apply (see zepbound.lilly.com/savings)
Terms valid through December 31, 2026.
Activate here: zepbound.lilly.com/savings
See complete savings card guide →
Save Your Card Details
After activating, save your BIN, PCN, and Group number (pharmacy processing codes). You'll need these at the pharmacy.
What to say at the pharmacy
When picking up your prescription:
"I have a Zepbound prescription with prior authorization. My PA reference number is [NUMBER]. I also have a Lilly savings card—here's the BIN and PCN. Can you confirm my copay before filling?"
Common pharmacy issues and fixes:
"PA not on file"
Ask them to call insurance or your doctor to verify. Say: "The PA was approved on [DATE]. Can you call the insurance PA department to verify the authorization?"
"Savings card not working"
Confirm the BIN and PCN are entered correctly. If still not working, call Lilly support at the number on your savings card.
"Not in stock"
Ask when it will be available or try another pharmacy. Some patients have better luck with specialty pharmacies.
How to prepare for Zepbound renewal
Monthly tracking (for your records and renewal):
- Weight (same scale, same conditions)
- Blood pressure
- A1C (quarterly)
- Side effects or issues
- Lifestyle activities (exercise, diet tracking)
60 days before expiration:
- Contact your doctor's office to initiate renewal
- Confirm you've met your plan's weight loss threshold (typically 5%)
- Gather documentation showing your progress
Don't Wait Until the Last Minute
A reauthorization is a new review, so allow time (most employer and ACA plans can take up to 15 days). Starting early prevents gaps in your medication supply.
Strategies for Restrictive Coverage
FORMULARY & TIER EXCEPTIONS
Strategies for Restrictive Coverage
FORMULARY & TIER EXCEPTIONSIf Zepbound is Not on Formulary → Formulary Exception
Your goal: Add Zepbound to your plan's covered drug list. What to do if Zepbound is not covered by insurance →
- Your prescriber submits the exception request (on individual and small-group ACA plans, you or your representative can also ask)
- Submit medical necessity documentation
- Include your obesity-related complications and clinical evidence
Timeline: Individual and small-group ACA plans must decide within 72 hours (24 hours if urgent); employer plans follow their own exception process (federal claims rules allow up to 15 days for a standard request)
If Zepbound is High-Tier → Request a Tier Exception
Your goal: Get Zepbound covered at a lower cost-sharing tier. Medicare Part D plans must offer tiering exceptions; commercial plans may or may not, so ask your plan.
- Contact your insurance's formulary exception department
- Have your doctor submit a tier exception request
- Include documentation of failed trials with preferred medications
Timeline: Depends on your plan; ask when you file
Appeals & Reauthorization
IF DENIED OR RENEWING
Appeals & Reauthorization
IF DENIED OR RENEWINGWhy Appeals Matter
Initial denials are a filter, not a final answer. Over 65% of commercial insurance appeals succeed when properly documented—yet fewer than 1% of denied claims are ever appealed.2 Insurers rely on patient inaction. See appeal success rate data →
Just got your denial letter? Start with our Zepbound Denied crisis guide for what to do right now.
Common denial reasons include "not medically necessary," step therapy requirements, and Zepbound not covered by insurance. Each has specific appeal strategies that work.
Common Denials → Your Move
Timeline: Internal appeal 30 days → External review 45 days
No Insurance Guide
SELF-PAY OPTIONS
No Insurance Guide
SELF-PAY OPTIONSNeed the Lowest Price Now?
If you're paying out of pocket and need the lowest price immediately: LillyDirect self-pay (KwikPen or vial) starts at $299/month.
How to use the Zepbound savings card without insurance
Without insurance coverage: $499/month for the single-dose pen; KwikPen: $299 / $399 / $449 a month by dose (KwikPen)
Eligibility:
- Must have commercial insurance (even if it doesn't cover Zepbound)
- Not for Medicare, Medicaid, TRICARE, VA or other government insurance
Important
You need insurance even if it doesn't cover the drug. If you're completely uninsured, use LillyDirect instead (see below).
How to get Zepbound through LillyDirect (cash pay)
KwikPen or vial pricing (most affordable option):
- 2.5 mg: $299/month
- 5 mg: $399/month
- 7.5–15 mg: $449/month (if refilled within 45 days)
See complete LillyDirect pricing guide →
Refill Within 45 Days
Refill within 45 days to keep the $449 price for higher doses. After 45 days, prices increase:
- 7.5 mg: $499
- 10 mg: $699
- 12.5 mg: $699
- 15 mg: $699
Where to get it: LillyDirect.com or Walmart pharmacy pickup
How to apply for Zepbound patient assistance
Lilly Cares Patient Assistance Program:
- Zepbound, Mounjaro and Foundayo are not on Lilly Cares’ medication list, so it is not a route to free Zepbound
- Eligibility for the drugs it does list: Uninsured or on Medicare Part D/Part B, with income limits of 300–500% of the federal poverty level by drug
- Medication list and application: lillycares.com
See complete patient assistance guide →
Worth Checking
Because Lilly Cares doesn't list Zepbound, the lower-cost routes are LillyDirect self-pay ($299–$449/month) or, if you have commercial insurance, the savings card.
TrumpRx.gov direct-purchase option (Live Now)
TrumpRx.gov launched February 5, 2026. TrumpRx lists the manufacturers’ own self-pay prices (not a separate, cheaper price):
- Price: Zepbound vials at Lilly’s self-pay prices, $299–$449/month (orders go through LillyDirect)
- Who can use it: Anyone—not limited to Medicare/Medicaid
- Medicare patients: The Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027) covers the Zepbound KwikPen only (not vials or single-dose pens) at $50 per monthly fill for those who qualify
Where Medicare Patients Should Start
If you have Medicare, check the Medicare GLP-1 Bridge first: $50 per monthly fill for the Zepbound KwikPen only (not vials or single-dose pens) if you have eligible Part D coverage, meet CMS's criteria and your prescriber gets prior authorization. If you don't qualify, Medicare patients can pay cash through LillyDirect ($299–$449/month), including by ordering through TrumpRx.gov.
Alternatives
OTHER GLP-1 OPTIONS
Alternatives
OTHER GLP-1 OPTIONSIf Zepbound remains inaccessible, several FDA-approved alternatives may provide similar benefits. New in April 2026: Foundayo is Eli Lilly's oral GLP-1 pill—no injections required. Other options include Wegovy, Saxenda, and off-label medications.
Zepbound vs Wegovy and Saxenda
In a head-to-head trial (SURMOUNT-5), Zepbound produced more weight loss than Wegovy (20.2% vs 13.7% at 72 weeks), but it's not your only option. Wegovy (semaglutide) and Saxenda (liraglutide) are two other GLP-1s approved by the FDA for weight loss.
When deciding which GLP-1 is right for you, consider your weight loss goals, insurance coverage, side effects and budget.
Zepbound vs Mounjaro and Ozempic
While Mounjaro and Ozempic are currently only approved by the FDA for treatment of Type 2 diabetes, it doesn't necessarily mean you won't be able to access these medications.
Insurers generally cover them only with a type 2 diabetes diagnosis, so they are generally not a covered alternative for weight loss; it depends on your plan and clinical profile.
All Coverage Options at a Glance
DECISION MATRIX
All Coverage Options at a Glance
DECISION MATRIX| Insurance Type | Best First Step | Timeline | Monthly Cost | What's Changing |
|---|---|---|---|---|
| Employer/ACA (Good odds) | Check benefits → Submit PA | Up to 15 days (federal limit); can be sooner | as little as $25 (with card, commercial only)5 | — |
| Medicare (OSA) (Case-by-case) | Get sleep study | Varies (sleep study, then Part D plan PA) | Varies by plan | Bridge (now): $50 per monthly fill for obesity, KwikPen only, if eligible |
| Medicaid (Case-by-case) | Check state coverage | Varies by state | $0 or a small copay | BALANCE Model: voluntary for states; no participating state confirmed |
| No Insurance (Self-pay only) | LillyDirect (KwikPen or vial) | Order anytime (delivery or Walmart pickup) | $299–$449 | — |
Color key: Good odds | Case-by-case | Self-pay only
Quick Path Summary
- Employer/ACA: Best coverage path. Check benefits, submit PA, appeal if denied.
- Medicare: The Medicare GLP-1 Bridge covers the Zepbound KwikPen for obesity at $50 per monthly fill if you qualify (July 1, 2026 – December 31, 2027). With moderate-to-severe sleep apnea, Zepbound may be covered under your Part D plan instead, subject to the plan's formulary, prior authorization and exceptions process.
- Medicaid: State-dependent. BALANCE Model: Voluntary for states, which can join between May 2026 and January 1, 2027; no participating state has been confirmed.
- No Insurance: LillyDirect self-pay (KwikPen or vial) costs $299–$449/month, less than the savings card's no-coverage price ($499/month).
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get startedImpressive and successful!
My doctor did not even try to appeal when zepbound was originally denied, and the thought of appealing myself was overwhelming. I found Honest Care online and was very impressed with the letter and support...
I was denied coverage of my zepbound due to my company changed their requirements. After going over the appeal letter with my doctor (she was incredibly impressed) we submitted and got approved within 48 hrs. Worth every penny.
Honest Care gets results!
My insurance refused prior authorization for Zepbound, but said I could file an appeal. My Appeal was approved the next day. Thank you Honest Care for helping me get my life back.
denied approved
Honest Care helps patients fight back:
Evidence-backed appeal letters — plus personalized guidance to appeal with confidence.
"I found Honest Care online and was very impressed with the letter... the appeal worked!"
"My Appeal was approved the next day. Thank you Honest Care!"
COMMON COVERAGE QUESTIONS
Frequently Asked Questions
Start by calling your insurer to check if Zepbound is on your formulary. If covered, your doctor submits a prior authorization (PA) with your BMI, comorbidities, and documentation of lifestyle changes. Follow up within 3-5 days. See our prior authorization guide for detailed requirements by insurer.
Gather before your appointment: current weight/height (for BMI calculation), list of comorbidities with diagnosis dates, documentation of lifestyle changes (diet logs, gym records), and history of prior weight-loss medications tried. See our PA checklist for a complete list.
Most employer and ACA plans must decide within 15 days (one 15-day extension allowed; 72 hours if urgent), and many decide sooner. Call to check status by day 5—don't wait for a letter. If no decision after 7 days, request escalation. See our PA guide for timelines by insurer.
You have the right to appeal. Get your denial letter, note the exact reason, and see our appeals guide for step-by-step instructions.
Now, with conditions. The Medicare GLP-1 Bridge runs July 1, 2026 – December 31, 2027 and covers the Zepbound KwikPen only (not vials or single-dose pens) for weight loss at $50 per monthly fill. Who qualifies: Age 18+ and BMI ≥35; or BMI ≥30 with HFpEF, uncontrolled high blood pressure or CKD stage 3a+; or BMI ≥27 with prediabetes, a prior heart attack or stroke, or symptomatic PAD. Not eligible if you have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH with moderate-to-advanced liver fibrosis (F2–F3), or if your Part D plan paid for a GLP-1 for you at any time in 2026. Part D plans and pharmacies don’t opt in, and you don’t enroll separately; your prescriber must get prior authorization. Longer-term Part D coverage under the BALANCE Model: Delayed, with no new start date. See our Medicare guide for eligibility details →
Yes. Many patients use LillyDirect ($299–$449/month) to start treatment while their PA or appeal processes. If insurance approves later, you can switch to using your coverage. See our cost guide for all payment options.
Start the renewal process 60 days before your authorization expires. Many insurers require proof of continued progress (for example, 5% weight loss; thresholds vary by plan). Track your weight monthly and confirm your plan's specific reauthorization criteria. Your doctor will submit updated documentation showing your progress and continued medical necessity.
References
- American Medical Association. (2023). "Over 80% of Prior Auth Appeals Succeed—Why Aren't There More?" ama-assn.org
- Kaiser Family Foundation. (2023). "Claims Denials and Appeals in ACA Marketplace Plans." Analysis of CMS data showing fewer than 1% of denied claims are appealed. kff.org
- Wilding JPH, et al. (2022). "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension." Diabetes Obes Metab. Note: This study is for semaglutide (Wegovy), but similar patterns are expected for GLP-1 class medications including tirzepatide (Zepbound). PubMed
- Harvard Health Publishing. (2024). "Prior Authorization: What Is It, When Might You Need It, and How Do You Get It?" health.harvard.edu; KFF 2025 Employer Health Benefits Survey kff.org; decision timelines: 29 CFR 2560.503-1(f) law.cornell.edu
- Eli Lilly and Company. (2025). "Zepbound Savings Card Program." zepbound.lilly.com
- 42 U.S.C. § 1395w-102. Medicare Part D Prescription Drug Benefits. law.cornell.edu
- U.S. Food and Drug Administration. (2024). "Zepbound Prescribing Information." fda.gov
- Kaiser Family Foundation. (2024). "Medicaid Coverage of and Spending on GLP-1s." kff.org
- State Medicaid policy documents: NC Medicaid, CA DHCS, NH Medicaid, MI Public Radio
- LillyDirect. (2025). "Zepbound Vial Pricing." lillydirect.com
- Express Scripts. (2025). "2026 National Preferred Formulary Exclusion List Changes." evernorth.com (PDF)
- Axios. (2025). "Trump announces Medicare coverage of weight-loss drugs." axios.com
Guide Introduction Statistics
- Washington State Office of the Insurance Commissioner. (2025). "Health Plan Prior Authorization Data 2024 Annual Report." Tirzepatide (listed as Mounjaro) had a 31.2% prior authorization approval rate across Washington carriers in plan year 2023. This is Washington-only, mostly the diabetes brand, and not a Zepbound denial rate. insurance.wa.gov (PDF)
- Kaiser Family Foundation. (2023). "Claims Denials and Appeals in ACA Marketplace Plans." Analysis of CMS data showing fewer than 1% of denied claims are appealed. kff.org
- American Medical Association. (2024). "Over 80% of prior auth appeals succeed. Why aren't there more?" 83.2% of prior authorization appeals were either partially or fully overturned in 2022. ama-assn.org
- Kaiser Family Foundation. (2025). "2025 Employer Health Benefits Survey." 43% of firms with 5,000+ workers, and 16% of firms with 200–999 workers (2025) covered GLP-1 drugs for weight loss. kff.org
- Axios. (November 6, 2025). "Trump announces Medicare coverage of weight-loss drugs." Announcement of Medicare coverage of GLP-1s for obesity at a $50/month copay (now the Medicare GLP-1 Bridge, July 1, 2026 – December 31, 2027). axios.com
- Eli Lilly. (2025). "LillyDirect: Zepbound Pricing." KwikPen or single-dose vials starting at $299/month; Zepbound Savings Card reduces copay to as little as $25/month with commercial insurance. lillydirect.com
Last updated October 6, 2026 · Key facts verified October 5, 2026 · Full page reviewed October 5, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.